Stocks
Pasithea Therapeutics Corp.KTTA
NASDAQHealthcareBiotechnology$0.42
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing novel therapies for central nervous system disorders, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis. Its lead candidate, PAS-003, is in early-stage trials, and the company also holds a portfolio of preclinical assets. Investors track KTTA for its pipeline progress and potential in the neurodegenerative disease space.
52W Range: $0.28-$2.06
Congressional Interest in Pasithea Therapeutics Corp. (KTTA)
No congressional trades have been disclosed for Pasithea Therapeutics Corp. (KTTA) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading KTTA?
No congressional trades found for this stock.